These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 28813559)
21. Updates on diagnosis and management of autoimmune blistering diseases. Cole EF; Sami N; Feldman RJ G Ital Dermatol Venereol; 2020 Feb; 155(1):46-64. PubMed ID: 31804056 [TBL] [Abstract][Full Text] [Related]
22. Intravenous immune globulin in autoimmune and inflammatory diseases. Gelfand EW N Engl J Med; 2012 Nov; 367(21):2015-25. PubMed ID: 23171098 [No Abstract] [Full Text] [Related]
23. Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions. Watad A; Amital H; Shoenfeld Y Lupus; 2017 Sep; 26(10):1015-1022. PubMed ID: 28420062 [TBL] [Abstract][Full Text] [Related]
24. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. Negi VS; Elluru S; Sibéril S; Graff-Dubois S; Mouthon L; Kazatchkine MD; Lacroix-Desmazes S; Bayry J; Kaveri SV J Clin Immunol; 2007 May; 27(3):233-45. PubMed ID: 17351760 [TBL] [Abstract][Full Text] [Related]
25. Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States. Bloom R; Amber KT J Am Acad Dermatol; 2015 Aug; 73(2):337-8. PubMed ID: 26183986 [No Abstract] [Full Text] [Related]
26. Management of autoimmune blistering diseases in Spain. Suárez R; España A; Herrero-González JE; Iranzo P; Mascaró JM Dermatol Clin; 2011 Oct; 29(4):673-6. PubMed ID: 21925016 [TBL] [Abstract][Full Text] [Related]
27. [IgIV at home:experience of a center--economic aspects]. Hachulla E Rev Med Interne; 2007 May; 28 Spec No. 1():7-10. PubMed ID: 17768832 [TBL] [Abstract][Full Text] [Related]
28. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases. Rütter A; Luger TA Curr Opin Investig Drugs; 2002 May; 3(5):713-9. PubMed ID: 12090544 [TBL] [Abstract][Full Text] [Related]
29. Intravenous immunoglobulin therapy: the process, the product, the patient, and the pocketbook. Introduction. Harvey RD Pharmacotherapy; 2005 Nov; 25(11 Pt 2):71S-72S. PubMed ID: 16229676 [No Abstract] [Full Text] [Related]
30. Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2). Smith DI; Swamy PM; Heffernan MP J Am Acad Dermatol; 2007 Jan; 56(1):e1-54. PubMed ID: 17190617 [TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin-induced, non-eczematous, vesiculobullous eruptions in Stevens-Johnson syndrome. Lin WL; Lin WC; Chang YC; Yang LC; Hung SI; Hong HS; Chung WH Am J Clin Dermatol; 2009; 10(5):339-42. PubMed ID: 19658448 [TBL] [Abstract][Full Text] [Related]
36. [Therapy with intravenous gammaglobulins in systemic inflammatory autoimmune diseases: new indications?]. Sánchez-Ramón S; Valor L Med Clin (Barc); 2014 Aug; 143(3):130-3. PubMed ID: 24480286 [No Abstract] [Full Text] [Related]
37. Approach to the patient with autoimmune mucocutaneous blistering diseases. Sami N Dermatol Ther; 2011; 24(2):173-86. PubMed ID: 21410607 [TBL] [Abstract][Full Text] [Related]